Group One Trading
SYRE icon

Group One Trading’s Spyre Therapeutics SYRE Stock Holding History

Group One Trading’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
+11,500
New +$839K ﹤0.01% 2850
2026
Q1 		– Sell
-100
Closed -$3.28K – 8714
2025
Q4 		$3.28K Buy
+100
New +$2.61K ﹤0.01% 7363
2024
Q2 		– Sell
-2,000
Closed -$75.9K – 7465
2024
Q1 		$75.9K Hold
2,000
– – ﹤0.01% 4379
2023
Q4 		$43K Sell
2,000
-600
-23% -$8.27K ﹤0.01% 5181
2023
Q3 		$31.9K Buy
+2,600
New +$34.4K ﹤0.01% 5499
2022
Q3 		– Sell
-84
Closed -$1K – 8238
2022
Q2 		$1K Buy
84
+72
+600% +$2.52K ﹤0.01% 7623
2022
Q1 		$1K Sell
12
-192
-94% -$16.1K ﹤0.01% 7878
2021
Q4 		$24K Buy
+204
New +$32.2K ﹤0.01% 6873
2021
Q3 		– Sell
-200
Closed -$35K – 8770
2021
Q2 		$35K Buy
200
+188
+1,567% +$34.2K ﹤0.01% 6859
2021
Q1 		$2K Buy
12
+4
+50% +$767 ﹤0.01% 7403
2020
Q4 		$2K Buy
8
+4
+100% +$829 ﹤0.01% 6273
2020
Q3 		$1K Buy
+4
New +$740 ﹤0.01% 5958

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Group One Trading's SYRE Position: Q2 2026 in Review

Group One Trading sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 901 shares — an estimated $65.7K sold.

Group One Trading first reported a position in SYRE in Q3 2020 and held it in 13 quarters. The position peaked at $45.4K in Q1 2026. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Group One Trading reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 901 Spyre Therapeutics shares in Q2 2026, an estimated $65.7K.
  • Group One Trading first reported a position in Spyre Therapeutics in Q3 2020 and held it in 13 quarters.
  • Group One Trading's Spyre Therapeutics position peaked at $45.4K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.